Accueil>>Signaling Pathways>> Others>>FPR Agonist 43

FPR Agonist 43 (Synonyms: FPR Agonist 43)

Catalog No.GC36075

FPR Agonist 43 (composé 43) est un double récepteur formyl-peptide 1 (FPR1) et formyl-peptide récepteur 2 (FPR2)/agoniste ALX.

Products are for research use only. Not for human use. We do not sell to patients.

FPR Agonist 43 Chemical Structure

Cas No.: 903895-98-7

Taille Prix Stock Qté
10mM (in 1mL DMSO)
188,00 $US
En stock
5mg
171,00 $US
En stock
10mg
261,00 $US
En stock
25mg
513,00 $US
En stock
50mg
819,00 $US
En stock
100mg
1 305,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

FPR Agonist 43 (compound 43) is a dual formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)/ALX agonist[1][2]. FPR1, FPR2/ALX[1]

FPR Agonist 43 (10-5-107 nM) is actively potent in the cAMP assay in FPR2/ALX over-expressing CHO cells[1]. FPR Agonist 43 is also active in the GTPγ binding assay (IC50=207±51 nM)[1].FPR1 is the preferred receptor for FPR Agonist 43 in in both human neutrophils and possibly also in mouse cells[2]. Cell Viability Assay[1] Cell Line: Chinese hamster ovary (CHO) over-expressing human FPR2/ALX receptors

[1]. PlanagumÀ A, et al. Lack of activity of 15-epi-lipoxin A? on FPR2/ALX and CysLT1 receptors in interleukin-8-driven human neutrophil function. Clin Exp Immunol. 2013 Aug;173(2):298-309. [2]. Forsman H, et al. What formyl peptide receptors, if any, are triggered by compound 43 and lipoxin A4• Scand J Immunol. 2011 Sep;74(3):227-234.

Avis

Review for FPR Agonist 43

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for FPR Agonist 43

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.